Abstract: Pseudopterosins and pseudopteroxazole are intriguing marine natural products that possess notable antimicrobial activity with a commensurate lack of cytotoxicity. New semi-synthetic pseudopteroxazoles, pseudopteroquinoxalines and pseudopterosin congeners along with simple synthetic mimics of the terpene skeleton were synthesized. In order to build structure-activity relationships, a set of 29 new and previously reported compounds was assessed for in vitro antimicrobial and cytotoxic activities. A number of congeners exhibited antimicrobial activity against a range of Gram-positive bacteria including Mycobacterium tuberculosis H 37 Rv, with four displaying notable antitubercular activity against both replicating and non-replicating persistent forms of M. tuberculosis. One new semi-synthetic compound, 21-((1H-imidazol-5-yl)methyl)-pseudopteroxazole (7a), was more potent than the natural products pseudopterosin and pseudopteroxazole and exhibited equipotent activity against both replicating and non-replicating persistent forms of M. tuberculosis with a near absence of in vitro cytotoxicity. Pseudopteroxazole also exhibited activity against strains of M. tuberculosis H 37 Rv resistant to six clinically used antibiotics.
Introduction
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB), a disease which remains a serious threat to the global human population, causing nearly 2 million deaths and over 9 million new infections annually [1] . While the majority of TB patients can be cured using existing antibiotic treatment regimens, several challenges still exist for the treatment of TB. A key drawback to current therapies is the lengthy duration (6-9 months) required to ensure complete eradication of the disease. The long duration and associated toxicity result in poor patient compliance which contributes to the spread of TB and selects for drug-resistant forms of the disease. The need for extended TB treatment regimens is in large part due to the resistance of non-replicating persistent (NRP) subpopulations of M. tuberculosis to antibiotic treatment. The treatment of TB is further complicated by the increasing occurrence of strains resistant to multiple drugs, which account for approximately 5% of TB cases [2] . To improve the outcome of existing TB treatments, new classes of molecules active against NRP-TB and emerging drug-resistant strains are greatly needed [3, 4] . Natural products represent an obvious starting point to meet this desideratum given that they have historically provided a wealth of antibiotic lead compounds which have been successfully developed into efficacious drugs [5] .
The diterpenes pseudopteroxazole (1) and homopseudopteroxazole (2) ( Figure 1 ) are trace marine natural products from Pseudopterogorgia elisabethae with reported activity against Mycobacterium tuberculosis H 37 Rv [6, 7] . Despite interest in 1 by the synthetic chemistry community [8] [9] [10] , no medicinal chemistry efforts around this scaffold were reported until our recent semi-synthesis of 1, 2 and 14 congeners from relatively abundant natural pseudopterosins G-J (3a-3d) [11] . In this earlier report we described activity against model mycobacteria (M. smegmatis and M. diernhoferi) and clinically relevant Gram-positive bacteria: methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VRE). The pseudopteroxazole pharmacophore is not known, thus an aim of the current study was to conduct a preliminary examination of structure-activity relationships (SAR), especially against M. tuberculosis H 37 Rv. In the previous report we examined the effect of modifying the oxazole moiety in 1 by synthesizing C-21 substituted derivatives of 1 and also by preparing isopseudopteroxazoles, which are pseudopteroxazole congeners where the location of the oxazole nitrogen and oxygen atoms are inverted. We found that appending lipophilic moieties to the C-21 oxazole decreased the antimicrobial activity against model mycobacteria, MRSA and VRE, whereas isopseudopteroxazoles and their corresponding pseudopteroxazoles exhibited similar antimicrobial activity [11] . We report herein the in vitro activity of the aforementioned pseudopteroxazole compound set and new structurally related compounds against M. tuberculosis H 37 Rv and a model of NRP-TB. Given that the pseudopterosins [12, 13] are also known to possess antibiotic activity against various Gram-positive bacteria [14] [15] [16] [17] including M. tuberculosis [15] , we aimed to synthesize and evaluate derivatives based on the parent aglycone scaffold of both pseudopterosins G-J and pseudopteroxazole. In this regard we have: (1) substituted the oxazole moiety in 1 with a pyrazine to generate pseudopteroquinoxaline (5); (2) synthesized a range of pseudopteroxazole derivatives such as 21-((1H-imidazol-5-yl)methyl)-pseudopteroxazole (7a) and the regioisomer (7b), which are pseudopteroxazoles with polar, amphoteric imidazole side chains that possess activity in a NRP-TB model; (3) examined the biological effect of altering the phenolic substituents on the pseudopterosins G-J aglycone (4); and (4) synthesized small prenylated phenol derivatives and related glycosides as mimics of the pseudopterosin/pseudopteroxazole structural core.
Results and Discussion

Chemistry
Pseudopteroxazoles (1, 2, 22-33) were synthesized as previously described [11] . The synthesis of the novel compounds is discussed below.
Synthesis of Pseudopteroquinoxalines 5 and 6
Pseudopteroquinoxaline (5) was synthesized in one-pot by oxidation of the pseudopterosin G-J aglycone (4) [18] with Ag 2 O and condensation with ethylenediamine (Scheme 1). In an alternative synthesis, treatment of 4 with Dess-Martin periodinane in DCM/MeOH, followed by reaction with ethylenediamine yielded 5 and the tertiary ether 6 as a minor side product. (ii) Δ, isopropyl alcohol, for 5 and 6.
Synthesis of Pseudopteroxazoles 7a and 7b
Synthesis of the novel derivatives 21-((1H-imidazol-5-yl)methyl)-pseudopteroxazole (7a) and the regioisomer (7b) followed the previously reported general method utilizing the aglycone (4), Ag 2 O and histidine (Scheme 2). After purification by flash chromatography, a mixture of 7a and 7b was obtained in a 2.4:1 ratio as determined by 1 H NMR analysis. This product regioisomer ratio differs from the ~10:1 ratio previously observed with other amino acids [11] . While the reasons behind this are under further investigation, it is conceivable that the nucleophilic imidazole attacks the ortho-quinone at C-10, which increases the relative rate of condensation at C-9. Separation of the regioisomers (7a/7b) proved challenging; while HPLC did not lead to peak resolution, a portion of the material was slightly enriched in 7a (3:1 ratio) by peak shaving. This material (7a/7b) has been thoroughly and unambiguously characterized; spectra and analytical chromatograms are provided in the supporting information. 
Synthesis of Pseudopterosin Derivatives 8-12
The mono-pentyl ether (8) derivative of the pseudopterosin G-J aglycone (4) was synthesized to provide a phenolic mimic of homopseudopteroxazole (2), given that 2 possesses a pentyl chain and was reportedly active against M. tuberculosis H 37 Rv [7] . The mono-pentyl ether (8) and mono-methyl ether (9) [19] were synthesized by alkylation of 3a-d with iodopentane or iodomethane, respectively, followed by acid catalyzed hydrolysis of the fucose moiety (Scheme 3). Further substitution of the free phenol in 9 by treatment with the appropriate electrophile yielded the di-methyl ether (10), the triflate (11) and the carbamate (12). 
Synthesis of Pseudopterosin Mimics 14-20
The syntheses of the prenylated aromatic mimics of pseudopterosin are shown in Scheme 4. Acid catalyzed reaction of 2,6-dimethoxyphenol (13) with 2-methyl-3-buten-2-ol yielded the mono-, di-and tri-prenylated derivatives (14, 15 & 16 [20] . Generally substitutions at the C-21 oxazole moiety in 1 lead to congeners with reduced activity against M. tuberculosis H 37 Rv, however, three compounds (7a/7b, 22 & 25) showed activity against M. tuberculosis H 37 Rv comparable to 1. Semi-synthetic homopseudopteroxazole (2) was not active against M. tuberculosis H 37 Rv in contrast to the literature report for natural 2 isolated from P. elisabethae, which was reported to show 80% inhibition against M. tuberculosis H 37 Rv at 12.5 μg/mL (40 μM) [7] . Our result with 2 was consistent with the inactivity of other members of the series with lipophilic C-21 substituents. As a measure of potential toxicity the IC 50 values of the pseudopteroxazoles against Vero cells [21] were determined, and the selectivity index was calculated (Vero cell IC 50 /M. tuberculosis H 37 Rv MIC). Only four semi-synthetic pseudopteroxazoles were non-toxic to Vero cells at 128 μg/mL: pseudopteroxazole (1), homopseudopteroxazole (2), the methionine derivative (27) and the histidine derivative (7a/7b, 4% toxicity at 128 μg/mL). Of these, two (1 and 7a/7b) exhibited antitubercular activity resulting in selectivity indices >8.6. The cytotoxicity result for 1 is comparable to that observed with "natural" pseudopteroxazole (1), which was reported to show no significant cytotoxicity against the NCI-60 cell line assay [6] . Interestingly, isopseudopteroxazole (22) displayed toxicity towards the Vero cells (IC 50 52 μg/mL), otherwise this regioisomer exhibited very similar antimicrobial activity to 1.
The pseudopteroxazoles were also tested at a single point concentration (64 μg/mL) in the low-oxygen-recovery assay (LORA), a model of NRP-TB [22] . Selected active compounds were further tested to determine LORA MICs; 7a/7b showed the strongest activity, with an MIC of 12 μg/mL ( Table 1) . As antibiotics acting on the cell wall are typically not active against NRP-TB, the LORA activity exhibited by pseudopteroxazole and several semi-synthetic congeners suggests that the target of these compounds is not the cell wall [22] .
The semi-synthetic histidine derivative (7a/7b) is the most promising of the pseudopteroxazoles as it was non-toxic, exhibited potent broad-spectrum Gram-positive antibiotic activity and was the most active compound in assays against replicating and NRP-TB (MABA and LORA, respectively). While the MIC of 7a/7b against M. tuberculosis H 37 Rv was moderate (13 μg/mL or 34 μM) in comparison to the first line drugs isoniazid and rifampin, its activity compares favorably to other first and second line TB treatments such as ethambutol (4.6-9.2 μM), kanamycin (2.5-10.3 μM), capreomycin (0.94-3.7 μM) and cycloserine (122-490 μM) [23] . One of the most promising attributes of 7a/7b was that it showed greater potency in LORA (LORA MIC 12 μg/mL or 31 μM) compared to 1 (LORA MIC 50 μg/mL or 162 μM). Activity against NRP-TB is highly desirable given this phenotype contributes to lengthy treatment regimens leading to poor patient compliance ultimately translating into increased TB transmission rates and selection for drug-resistant strains [4] . As shortening of treatment times is a key goal of current TB chemotherapeutic research, this compound may represent a starting point for developing drugs that are more efficacious towards latent TB infections [1] .
Recently a diterpene that is structurally related to pseudopterosins has been shown to possess activity against M. tuberculosis H 37 Rv and a multidrug-resistant strain [24] . These examples suggest that the semi-synthetic pseudopteroxazole congeners may also display activity against drug-resistant strains. Thus, we determined MICs of 1 against six isogenic mono-resistant M. tuberculosis H 37 Rv strains (Table 2 ). In our study the six strains tested were singly-resistant to a structurally diverse group of antibiotics targeting a variety of cellular targets. The aminoglycosides streptomycin and kanamycin target the 30S ribosome, the fluoroquinolone moxifloxacin targets DNA gyrase, the ansamycin antibiotic rifampin targets RNA polymerase and the small heterocyclic antibiotics isoniazid and cycloserine inhibit cell wall biosynthesis, albeit via distinct mechanisms [25] [26] [27] . Pseudopteroxazole exhibited virtually identical activity against wild-type and antibiotic resistant strains. While 1 was significantly less potent than rifampin and isoniazid none of the antibiotic resistant strains exhibited cross-resistance to 1, suggesting that it may exert its antimicrobial activity via a unique mode of action. The biological data of the pseudopterosin derivatives (including the pseudopteroquinoxalines) and of the prenylated aromatic mimics of pseudopterosins are summarized in Table 3 . These compounds were tested in vitro against MRSA, VRE, M. smegmatis (ATCC 12051), and M. diernhoferi (ATCC 19340) using microbroth dilution antibiotic susceptibility assays. The compounds were also assessed for activity against M. tuberculosis, Vero cells and in the LORA. Natural pseudopterosins G-J (3a-d) showed the strongest activity against all pathogens, and exhibited low toxicity towards Vero cells. The mono-methyl ether (9) retained some activity against all pathogens; however, all other semi-synthetic derivatives showed significantly reduced activity against one or more organisms. Pseudopteroquinoxaline (5) was moderately active against the three mycobacteria; however, it was toxic towards the Vero cells. The activity of the prenylated aromatic mimics is interesting: the mono-prenylated compound (14) was only weakly active against M. smegmatis and M. diernhoferi; the tri-prenylated compound (16) showed moderate activity against M. diernhoferi, and was also active against VRE and M. tuberculosis; the di-prenylated compound (15) was the most active as it showed good to moderate activity against all bacteria with an IC 50 of 3 μg/mL against VRE. To provide a glycoside mimic of pseudopterosins, the galactoside derivative 20 was synthesized from 14. This synthetic galactoside was less active than the parent prenylated mimic and no additional glycosides were synthesized following unsuccessful glycosylation attempts utilizing the di-prenylated compound (15) . The activity of the prenylated aromatics hints at the possibility of a simpler pharmacophore than the natural diterpene skeleton. However, more work is required here as it does not necessarily follow that these mimics operate through the same mechanism of action as the pseudopterosins/pseudopteroxazoles.
Relevance of the Use of Model Mycobacteria
Due to the challenges associated with cultivating M. tuberculosis (slow growth rate, biosafety risk, biosafety level 3 containment requirements) we initially used two fast growing mycobacteria, M. smegmatis and M. diernhoferi, as model organisms to evaluate the antimycobacterial activity of the compounds described herein. The usefulness of fast growing mycobacteria to detect compounds inhibitory to the growth of TB, particularly the widely used M. smegmatis, has recently been questioned. In a comprehensive study of the relative activity of 5000 compounds against M. smegmatis and M. tuberculosis, 50% of compounds active against M. tuberculosis were not detected as active against M. smegmatis [27] . Despite this disparity, the use of fast growing mycobacterial models continue to have utility as a whole cell screen against M. smegmatis identified the promising new diarylquinoline, TMC207, which is currently in Phase II-III clinical trials for the treatment of multidrug-resistant TB [1] . In the evaluation of the series of pseudopteroxazole congeners the model mycobacteria were good predictors of antimycobacterial activity (Tables 1 and 3 , and previously published data [11] ). There were no instances of false-negative predictions (i.e., the model organisms were insensitive to a compound which inhibited the growth of M. tuberculosis). However, there were a few instances where the model organisms predicted activity which was not mirrored by M. tuberculosis in the MABA (4, 27, 28, 31) . Interestingly, in three of these cases significant activity was observed in the LORA. These observations suggest that model mycobacteria can be a reliable predictor of M. tuberculosis activity for a particular series of molecules.
Experimental Section
General Experimental Procedures
The MABA, LORA and Vero cell assays were all conducted by the Institute for Tuberculosis Research following published protocols [20] [21] [22] . NMR spectra were obtained on a Bruker Avance III 600 MHz NMR spectrometer operating at 600 and 150 MHz for (5) A sample of pseudopterosin G-J (3a-d, 20 mg, 0.041 mmol) was refluxed in methanolic HCl (1.5 N, 10 mL) under N 2 for 2.5 h. The crude mixture was then partitioned between EtOAc and H 2 O and the EtOAc phase was concentrated in vacuo to give the crude aglycone (4). This material was dissolved in EtOH (15 mL) and air was bubble through the sample for 10 min. Ethylenediamine (50 μL, excess) and Ag 2 O (14 mg, 0.065 mmol) were then added and the reaction was refluxed for 1.5 h. The reaction mixture was then filtered through Celite and partitioned between EtOAc and H 2 O. The EtOAc phase was subjected to the standard work up procedure and then purified by flash chromatography (Silica, hexane→MTBE gradient) to give 5 (2 mg, 0.0063 mmol, 15% over two steps). 
Synthesis
Synthesis of Pseudopteroquinoxaline
Synthesis of 14,15-Dihydro-15-methoxy-pseudopteroquinoxaline (6)
To a solution of the pseudopterosin aglycone (4, 26.3 mg, 0.088 mmol) in DCM (10 mL + 100 μL H 2 O) was added Dess-Martin periodinane (68 mg, 0.16 mmol). After stirring for 15 min, MeOH (2 mL) and ethylenediamine (1 mL) were added. After another 45 min the solvent was removed in vacuo, and then isopropyl alcohol was added (20 mL). After refluxing overnight additional ethylenediamine (200 μL) was added and the solution was refluxed for a further 24 h. The reaction products were partitioned between EtOAc and H 2 O and the organic phase was subjected to the standard work up procedure to give an orange brown gum (31.8 mg). Purification by flash chromatography (diol modified silica, hexane→MTBE gradient) yielded the quinoxaline (5, 4.6 mg, 16%) and the methyl ether (6, 1.6 mg, 5%). 
Synthesis of 21-((1H-Imidazol-5-yl)methyl)-pseudopteroxazole (7a) and 21-((1H-Imidazol-5-yl)methyl)-isopseudopteroxazole (7b)
The pseudopteroxazole C-21 (1H-imidazol-4-yl)methyl derivatives (7a and 7b) were synthesized from the pseudopterosin aglycone (4, 193 mg, 0.64 mmol), Ag 2 CO 3 (1.4 equiv.) and histidine (6.7 equiv.) following the previously reported general procedure [11] . After purification by flash chromatography (diol modified silica, hexane→MTBE gradient) the product was obtained in 23% isolated yield (57.5 mg, 2.4:1 ratio of 7a/7b). A portion of this material was subjected to RP-HPLC (Phenomenex, phenylhexyl, 5 μm, 250 × 10 mm, 2.9 mL/min) eluted with MeOH:H 2 O:HCO 2 H (70:30:0.1). While the regioisomers eluted as one asymmetric peak (19.8 to 20.7 min), peak shaving lead to the isolation of an enriched fraction (3:1 ratio of normal to inverse regioisomer), which was the material used for biological evaluation. (8) A solution of pseudopterosins G-J (3a-d, 102 mg, 0.2 mmol), K 2 CO 3 (1 g, excess) and iodopentane (2 mL, excess) in anhydrous acetone was refluxed under N 2 for 18 h. The products were then partitioned between EtOAc and H 2 O and subjected to the standard work up procedure to give an orange/brown oil (127 mg). This crude product was then dissolved in 1.5 M HCl in MeOH (10 mL) and refluxed under N 2 for 2 h. The products were partitioned between EtOAc and H 2 O and the organic subjected to the standard work up procedure to yield the crude product, which was then purified by flash chromatography (C18, H 2 O→MeOH gradient) to yield the pentyl ether (8) (40.3 mg, 0.11 mmol, 52% over 2 steps). 3.2.5. Synthesis of 9,10-Dimethoxy-pseudopterosin G-J Aglycone (10) A stirred solution of 9 [19] (25.5 mg, 0.083 mmol) in dry THF (5 mL), under N 2 , was allowed to react with an excess of NaH for 2 h. Iodomethane (200 μL, excess) was then added and the solution was left stirring at room temperature overnight. The reaction was then carefully quenched with MeOH (1 mL), and excess iodomethane was removed under a stream of N 2 . The products were then partitioned between EtOAc and H 2 O. The EtOAc fraction was subjected to the standard work up procedure to give the crude product which was purified by flash chromatography (silica, hexane→MTBE gradient) to yield the desired dimethyl ether (10) 11 (s, 3H), 2.00 (m, 1H), 1.76 (br s, 3H), 1.71 (br s, 3H), 1.39 (m, 1H),  1.31-1.23 (m, 2H), 1.28 (d, 3H, 149.4, 149.0, 135.3, 134.0, 133.0, 130.9, 128.5, 128.4, 60.1, 59.8, 44.0, 40.1, 37.3, 34.0,  31.3, 28.3, 27.5, 25.4, 24.3 3.2.6. Synthesis of 9-Trifluoromethylsulfonyloxy-10-methoxy-pseudopterosin G-J Aglycone (11) Triflic anhydride (6 mmol) in DCM was added to a stirred, ice-cooled solution of 9 (178 mg, 0.56 mmol) and Hunig's base (2 mL) in dry toluene (8 mL). The reaction was stirred under N 2 , and allowed to warm to room overnight before being partitioned between DCM and aqueous HCl (1 N). The organic phase was subjected to the standard work up procedure to yield the crude triflate; purification was achieved by flash chromatography (silica, hexane→EtOAc gradient) to yield the triflate (11, 177 mg, 0.4 mmol, 70%, ~90% pure by ELSD LCMS). A portion of the product was further purified by RP-HPLC (Phenomenex, phenylhexyl, 5 μm, 250 × 10 mm, 4.0 mL/min) using a gradient of MeOH/H 2 O (9:1 for 1 min, then to 10:0 over 1-4 min; eluted across 9.9 to 10.25 min). 3.2.7. Synthesis of 9-Dimethylcarbamoyloxy-10-methoxy-pseudopterosin G-J Aglycone (12) A stirred solution of 9 (25.5 mg, 0.083 mmol) in dry THF (5 mL), under N 2 , was allowed to react with an excess of NaH for 2 h. Dimethylcarbamoyl chloride (200 μL, excess) was then added and the solution was stirred overnight. The reaction was then carefully quenched with MeOH (1 mL) and the products were portioned between EtOAc and H 2 O. The EtOAc fraction was subjected to the standard work up procedure to give the crude product which was purified by flash chromatography (silica, hexane→MTBE gradient) to yield the carbamate (12, 13.7 mg, 0.035 mmol, 43%). A solution of 2-methyl-3-buten-2-ol (640 mg, 7.4 mmol) in DCM (3 mL) was added dropwise to a stirred mixture of 2,6-dimethoxyphenol (13, 612 mg, 3.97 mmol) and TsOH (19 mg, cat) in DCM/MeOH (3:1, 30 mL). After stirring for 96 h at room temperature the solution was refluxed for 20 h and then partitioned between H 2 O and EtOAc. The organic phase was subjected to the standard work up procedure to yield a crude oil (793 mg) which was subjected to flash chromatography (C18, H 2 O→MeOH gradient) to yield the mono-prenylated product (14, 239 mg, 1.08 mmol, 27%), the di-prenylated product (15, 96 mg, 0.33 mmol, 8%), and the triprenylated product (16, 20 mg, 0.055 mmol, 1.4%) along with recovered starting material (321 mg, 52%). The glycosyl donor was synthesized from 2,3,4,6-tetra-O-benzoyl-α-D-galactopyranosyl bromide, which was freshly prepared using a previously described method [28] . The glycosyl bromide (2.05 g, 3.11 mmol) was hydrolyzed and subsequently reacted with trichloroacetonitrile according to existing methodology to provide the glycosyl donor 21 (704 mg, 0.951 mmol, 31% over two steps) [29] . The glycosylation procedure, described for the synthesis of 17, was repeated using the benzoylated glycosyl donor (21, The deprotection procedure, described for the synthesis of 18, was repeated with 19 (38.5 mg, 48.1 μmol) and K 2 CO 3 (33.4 mg). The deprotected glycoside was purified with the method described for 17 to yield 20 (13.9 mg, 36.2 μmol, 75%). 
Conclusions
In conclusion, we have synthesized a series of pseudopterosin and pseudopteroxazole derivatives, including simple prenylated aromatic diterpene mimics, and evaluated their antimicrobial activity against M. tuberculosis H 37 Rv, M. smegmatis, M. diernhoferi, MRSA and VRE. The major SAR emanating from this study pertains to the C-9 and C-10 substituents off the natural pseudopterosin-like scaffold. Variability in this region is tolerated for activity against M. tuberculosis H 37 Rv and other Gram-positive pathogens, such as MRSA and VRE. For instance, the phenolic (e.g., 9), benzoxazole (e.g., 7a), and quinoxaline (e.g., 5) derivatives all retained activity, though the latter was inactive against MRSA and VRE. Appropriate substitution at the C-9/C-10 position can lead to improved activity. In terms of Vero cell activity, while pseudopterosins (3a-d) did not display toxicity, a priori pseudopteroxazoles or other non-phenolic derivatives may represent better candidates for development since pseudopterosins may potentially be metabolized to the reactive ortho-quinone (4) or related derivatives.
It is likely that pseudopterosins and pseudopteroxazoles operate through a similar, and potentially novel, mechanism of action. We have commenced studies aiming to identify the antimicrobial mechanism of action of the pseudopteroxazoles and have begun investigating the effect of modifying other regions of the scaffold on biological activity.
